NanoVibronix, Inc. (NASDAQ:NAOV) Director Purchases $24,000.00 in Stock

NanoVibronix, Inc. (NASDAQ:NAOVGet Rating) Director Christopher M. Fashek bought 40,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 15th. The shares were purchased at an average cost of $0.60 per share, for a total transaction of $24,000.00. Following the purchase, the director now owns 75,000 shares in the company, valued at approximately $45,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

NAOV stock traded down $0.04 during mid-day trading on Friday, reaching $0.55. The company had a trading volume of 199,376 shares, compared to its average volume of 906,719. The firm has a fifty day simple moving average of $0.69 and a 200 day simple moving average of $0.84. NanoVibronix, Inc. has a fifty-two week low of $0.48 and a fifty-two week high of $4.19.

A number of hedge funds have recently bought and sold shares of NAOV. State Street Corp acquired a new stake in NanoVibronix in the 2nd quarter valued at about $35,000. Geode Capital Management LLC raised its position in NanoVibronix by 46.7% in the 3rd quarter. Geode Capital Management LLC now owns 200,752 shares of the company’s stock valued at $413,000 after purchasing an additional 63,868 shares in the last quarter. Morgan Stanley acquired a new stake in NanoVibronix in the 3rd quarter valued at about $40,000. Two Sigma Investments LP acquired a new stake in NanoVibronix in the 3rd quarter valued at about $333,000. Finally, Squarepoint Ops LLC acquired a new stake in NanoVibronix in the 3rd quarter valued at about $57,000. 6.80% of the stock is currently owned by institutional investors.

About NanoVibronix (Get Rating)

NanoVibronix, Inc, through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its principal products include UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device, which facilitates tissue regeneration and wound healing.

Recommended Stories

Want More Great Investing Ideas?

Receive News & Ratings for NanoVibronix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NanoVibronix and related companies with MarketBeat.com's FREE daily email newsletter.